Guardant Health Inc: Revolutionizing Cancer Diagnosis and Treatment
Cancer is one of the deadliest diseases in the world. According to the World Health Organization, cancer is the second leading cause of death globally, responsible for an estimated 9.6 million deaths in 2018. Cancer diagnosis and treatment have come a long way in recent times, and Guardant Health Inc is playing a significant role in this revolution.
What is Guardant Health Inc?
Guardant Health Inc is a leading precision oncology company focused on developing liquid biopsy tests, which help oncologists in better cancer diagnosis and treatment. The company’s mission is to conquer cancer with data.
Guardant Health Inc was founded in 2012 and is headquartered in Redwood City, California, USA. The company has developed non-invasive liquid biopsy tests based on proprietary technology, which can detect cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) in the blood of cancer patients. These liquid biopsy tests help oncologists in cancer diagnosis, treatment selection, and monitoring of disease progression.
How is Guardant Health Inc changing the cancer diagnosis and treatment landscape?
Traditionally, cancer diagnosis and treatment have relied on invasive procedures like tissue biopsies, which can be painful for the patient. Moreover, these procedures also carry the risk of complications. Guardant Health Inc’s liquid biopsy tests enable non-invasive cancer diagnosis and monitoring, as they require just a simple blood draw.
Guardant360 is Guardant Health Inc’s flagship liquid biopsy test, which can detect actionable genomic alterations in solid tumors. The test examines over 70 genes associated with cancer and is highly sensitive and specific. GuardantOMNI is another liquid biopsy test offered by the company, which can detect genomic alterations for therapy selection across all solid tumor types.
Guardant Health Inc’s liquid biopsy tests have been extensively validated in clinical studies and have demonstrated their clinical utility in cancer diagnosis, treatment selection, and monitoring. These tests have also been shown to be cost-effective compared to traditional tissue-based biopsies.
What are the benefits of Guardant Health Inc’s liquid biopsy tests?
Guardant Health Inc’s liquid biopsy tests offer several benefits over traditional tissue biopsy, including:
1) Non-invasive and painless for the patient, requiring just a simple blood draw.
2) Highly sensitive and specific, with a lower risk of false negatives compared to tissue biopsy.
3) Faster turnaround time, with results available within days compared to weeks for tissue biopsy.
4) Can detect mutations that tissue biopsy may miss, as some tumors can be difficult to biopsy or have insufficient tissue for analysis.
5) Can be used for treatment monitoring, allowing oncologists to adjust treatment plans based on real-time molecular changes in the tumor.
Conclusion
Guardant Health Inc is revolutionizing cancer diagnosis and treatment with its non-invasive, liquid biopsy tests. These tests offer several benefits over traditional tissue biopsy, including faster turnaround time, greater sensitivity and specificity, and the ability to monitor treatment in real-time. With its mission to conquer cancer with data, Guardant Health Inc is poised to play a significant role in the future of precision oncology.
(Note: Do you have knowledge or insights to share? Unlock new opportunities and expand your reach by joining our authors team. Click Registration to join us and share your expertise with our readers.)
Speech tips:
Please note that any statements involving politics will not be approved.